Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Prospective study of neuropeptide y as an adverse cardiovascular risk factor in end-stage renal disease.

Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Parlongo S, Cutrupi S, Iellamo D, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Cataliotti A, Malatino LS.

J Am Soc Nephrol. 2003 Oct;14(10):2611-7.

2.

Fibrinogen, mortality and incident cardiovascular complications in end-stage renal failure.

Zoccali C, Mallamaci F, Tripepi G, Cutrupi S, Parlongo S, Malatino LS, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Stancanelli B, Nicocia G, Buemi M.

J Intern Med. 2003 Aug;254(2):132-9.

3.

Chlamydia pneumoniae, overall and cardiovascular mortality in end-stage renal disease (ESRD).

Zoccali C, Mallamaci F, Tripepi G, Parlongo S, Cutrupi S, Benedetto FA, Bonanno G, Seminara G, Fatuzzo P, Rapisarda F, Malatino LS.

Kidney Int. 2003 Aug;64(2):579-84.

4.

Neuropeptide Y, left ventricular mass and function in patients with end stage renal disease.

Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Parlongo S, Cutrupi S, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Cataliotti A, Malatino LS.

J Hypertens. 2003 Jul;21(7):1355-62.

PMID:
12817184
5.

Fibrinogen, inflammation and concentric left ventricular hypertrophy in chronic renal failure.

Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Cutrupi S, Parlongo S, Malatino LS, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Nicocia G, Buemi M.

Eur J Clin Invest. 2003 Jul;33(7):561-6.

PMID:
12814392
6.

Adiponectin is markedly increased in patients with nephrotic syndrome and is related to metabolic risk factors.

Zoccali C, Mallamaci F, Panuccio V, Tripepi G, Cutrupi S, Parlongo S, Catalano F, Tanaka S, Ouchi N, Kihara S, Funahashi T, Matsuzawa Y.

Kidney Int Suppl. 2003 May;(84):S98-102.

PMID:
12694320
7.

Adiponectin in essential hypertension.

Mallamaci F, Zoccali C, Cuzzola F, Tripepi G, Cutrupi S, Parlongo S, Tanaka S, Ouchi N, Kihara S, Funahashi T, Matsuzawa Y.

J Nephrol. 2002 Sep-Oct;15(5):507-11.

PMID:
12455716
8.

Diagnostic value of troponin T for alterations in left ventricular mass and function in dialysis patients.

Mallamaci F, Zoccali C, Parlongo S, Tripepi G, Benedetto FA, Cutrupi S, Bonanno G, Fatuzzo P, Rapisarda F, Seminara G, Stancanelli B, Bellanuova I, Cataliotti A, Malatino LS; Cardiovascular Risk Extended Evaluation in Dialysis Investigators.

Kidney Int. 2002 Nov;62(5):1884-90.

9.

Low parathyroid hormone and pentosidine in hemodialysis patients.

Panuccio V, Mallamaci F, Tripepi G, Parlongo S, Cutrupi S, Asahi K, Miyata T, Zoccali C.

Am J Kidney Dis. 2002 Oct;40(4):810-5.

PMID:
12324917
10.

Norepinephrine and concentric hypertrophy in patients with end-stage renal disease.

Zoccali C, Mallamaci F, Tripepi G, Parlongo S, Cutrupi S, Benedetto FA, Cataliotti A, Malatino LS; CREED investigators.

Hypertension. 2002 Jul;40(1):41-6.

PMID:
12105136
11.

Troponin is related to left ventricular mass and predicts all-cause and cardiovascular mortality in hemodialysis patients.

Mallamaci F, Zoccali C, Parlongo S, Tripepi G, Benedetto FA, Cutrupi S, Bonanno G, Fatuzzo P, Rapisarda F, Seminara G, Stancanelli B, Bellanuova I, Cataliotti A, Malatino LS.

Am J Kidney Dis. 2002 Jul;40(1):68-75.

PMID:
12087563
12.

Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease.

Zoccali C, Mallamaci F, Parlongo S, Cutrupi S, Benedetto FA, Tripepi G, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Cataliotti A, Stancanelli B, Malatino LS.

Circulation. 2002 Mar 19;105(11):1354-9. Erratum in: Circulation 2002 May 7;105(18):2230. Cateliotti A [corrected to Cataliotti A].

PMID:
11901048
13.

Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease.

Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, Parlongo S, Malatino LS, Bonanno G, Seminara G, Rapisarda F, Fatuzzo P, Buemi M, Nicocia G, Tanaka S, Ouchi N, Kihara S, Funahashi T, Matsuzawa Y.

J Am Soc Nephrol. 2002 Jan;13(1):134-41.

14.

Circulating natriuretic peptide concentrations in patients with end-stage renal disease: role of brain natriuretic peptide as a biomarker for ventricular remodeling.

Cataliotti A, Malatino LS, Jougasaki M, Zoccali C, Castellino P, Giacone G, Bellanuova I, Tripepi R, Seminara G, Parlongo S, Stancanelli B, Bonanno G, Fatuzzo P, Rapisarda F, Belluardo P, Signorelli SS, Heublein DM, Lainchbury JG, Leskinen HK, Bailey KR, Redfield MM, Burnett JC Jr.

Mayo Clin Proc. 2001 Nov;76(11):1111-9.

PMID:
11702899
15.

Long-term CAPD patients are volume expanded and display more severe left ventricular hypertrophy than haemodialysis patients.

Enia G, Mallamaci F, Benedetto FA, Panuccio V, Parlongo S, Cutrupi S, Giacone G, Cottini E, Tripepi G, Malatino LS, Zoccali C.

Nephrol Dial Transplant. 2001 Jul;16(7):1459-64.

PMID:
11427641
16.

Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients.

Zoccali C, Mallamaci F, Benedetto FA, Tripepi G, Parlongo S, Cataliotti A, Cutrupi S, Giacone G, Bellanuova I, Cottini E, Malatino LS; Creed Investigators.

J Am Soc Nephrol. 2001 Jul;12(7):1508-15.

17.

Urinary adrenomedullin is related to ET-1 and salt intake in patients with mild essential hypertension. Salt Sensitivity Group of Italian Society of Hypertension.

Cuzzola F, Mallamaci F, Tripepi G, Parlongo S, Cutrupi S, Cataliotti A, Stancanelli B, Malatino L, Bellanuova I, Ferri C, Galletti F, Filigheddu F, Glorioso N, Strazzullo P, Zoccali C.

Am J Hypertens. 2001 Mar;14(3):224-30.

PMID:
11281233
18.

Diagnostic potential of cardiac natriuretic peptides in dialysis patients.

Mallamaci F, Zoccali C, Tripepi G, Benedetto FA, Parlongo S, Cataliotti A, Cutrupi S, Giacone G, Bellanuova I, Stancanelli B, Malatino LS; CREED Investigstors. The Cardiovascular Risk Extended Evaluation.

Kidney Int. 2001 Apr;59(4):1559-66.

19.

Gender-dependent differences in plasma leptin in essential hypertension.

Mallamaci F, Cuzzola F, Tripepi G, Cutrupi S, Parlongo S, Tripepi R, Zoccali C.

Am J Hypertens. 2000 Aug;13(8):914-20.

PMID:
10950400
20.

Renal endothelin-1 is linked to changes in urinary salt and volume in essential hypertension. Salt Sensitivity Group of the Italian Society of Hypertension.

Malatino LS, Bellanuova I, Cataliotti A, Cuzzola F, Mallamaci F, Tripepi G, Parlongo S, Cutrupi S, Mangiafico RA, Ferri C, Galletti F, Glorioso N, Strazzullo P, Zoccali C.

J Nephrol. 2000 May-Jun;13(3):178-84.

PMID:
10928293
21.

Smoking, blood pressure and serum albumin are major determinants of carotid atherosclerosis in dialysis patients. CREED Investigators. Cardiovascular Risk Extended Evaluation in Dialysis patients.

Malatino LS, Benedetto FA, Mallamaci F, Tripepi G, Zoccali C, Parlongo S, Cutrupi S, Marino C, Panuccio V, Garozzo M, Candela V, Bellanuova I, Cataliotti A, Rapisarda F, Fatuzzo P, Bonanno G, Seminara G, Stancanelli B, Tassone F, Labate C.

J Nephrol. 1999 Jul-Aug;12(4):256-60.

PMID:
10493569
22.

Bone density study of thalassemic patients from Reggio Calabria Province.

D'Ascola DG, Caminiti M, Mariano GP, Giuffrè C, Parlongo S, Meduri P, Brugiatelli M.

J Pediatr Endocrinol Metab. 1998;11 Suppl 3:963-4. No abstract available.

PMID:
10091173
23.

Plasma adrenomedullin during acute changes in intravascular volume in hemodialysis patients.

Mallamaci F, Zoccali C, Parlongo S, Cutrupi S, Tripepi G, Postorino M.

Kidney Int. 1998 Nov;54(5):1697-703.

24.

The influence of volume depletion and central hypovolemia on the plasma concentration of parathyroid hormone in dialysis patients.

Mallamaci F, Zoccali C, Messineo L, Parlongo S, Postorino M.

J Am Soc Nephrol. 1997 Oct;8(10):1574-8.

25.

Severe rhabdomyolysis induced by a retard formulation of bezafibrate in a CAPD patient.

Panuccio V, Enia G, Parlongo S, Cutrupi S, Zoccali C.

Nephron. 1996;73(4):736. No abstract available.

26.
27.

Urinary and plasma endothelin 1 in essential hypertension and in hypertension secondary to renoparenchymal disease.

Zoccali C, Leonardis D, Parlongo S, Mallamaci F, Postorino M.

Nephrol Dial Transplant. 1995;10(8):1320-3.

PMID:
8538921
28.
29.

Influence of extracellular volume expansion on circulating PTH1-84 in subjects with mild essential hypertension.

Zoccali C, Mallamaci F, Cuzzola F, Leonardis D, Postorino M, Parlongo S, Messineo L.

Am J Hypertens. 1994 Nov;7(11):960-4.

PMID:
7848622
30.
31.

The influence of autonomic failure on plasma ANF concentration in uremic patients on chronic hemodialysis.

Zoccali C, Mallamaci F, Ciccarelli M, Parlongo S, Salnitro F.

Clin Nephrol. 1992 Apr;37(4):198-203.

PMID:
1533821
32.

Hyperfiltration and calcium metabolism in essential hypertension.

Zoccali C, Mallamaci F, Postorino M, Cuzzola F, Leonardis D, Parlongo S, Salnitro F.

Am J Hypertens. 1991 Dec;4(12 Pt 1):944-50.

PMID:
1815651
33.

Mechanism of hypercalciuria in essential hypertension and in primary nephrolithiasis.

Zoccali C, Mallamaci F, Curatola G, Cuzzola F, Postorino M, Parlongo S, Salnitro F, Curatola A.

Contrib Nephrol. 1991;90:49-53.

PMID:
1959354
34.

The reflex control of vasopressin in haemodialysis patients.

Zoccali C, Mallamaci F, Ciccarelli M, Parlongo S, Salnitro F, Curatola A.

Nephrol Dial Transplant. 1991;6(9):631-6.

PMID:
1745386
35.

Double-blind randomized, crossover trial of calcium supplementation in essential hypertension.

Zoccali C, Mallamaci F, Delfino D, Ciccarelli M, Parlongo S, Iellamo D, Moscato D, Maggiore Q.

J Hypertens. 1988 Jun;6(6):451-5.

PMID:
3045202
36.

Effect of ultrafiltration on plasma concentrations of atrial natriuretic peptide in haemodialysis patients.

Zoccali C, Ciccarelli M, Mallamaci F, Delfino D, Salnitro F, Parlongo S, Maggiore Q.

Nephrol Dial Transplant. 1986;1(3):188-91.

PMID:
2955254
37.

Blood temperature and cardiovascular stability in hemofiltration.

Pizzarelli F, Sisca S, Zoccali C, Parlongo S, Nicolò F, Creazzo G, Delfino D, Maggiore Q.

Int J Artif Organs. 1983 Jan;6(1):37-41.

PMID:
6840887
38.

Blood temperature and vascular stability during hemodialysis and hemofiltration.

Maggiore Q, Pizzarelli F, Sisca S, Zoccali C, Parlongo S, Nicolò F, Creazzo G.

Trans Am Soc Artif Intern Organs. 1982;28:523-7. No abstract available.

PMID:
7164293
39.

Effect of extracorporeal blood cooling on dialytic arterial hypotension.

Maggiore Q, Pizzarelli F, Zoccali C, Sisca S, Nicolò F, Parlongo S.

Proc Eur Dial Transplant Assoc. 1981;18:597-602. No abstract available.

PMID:
7329988
40.

[Incidence and genesis of idiopathic hypercalciuria in calcic urolithiasis in a southern area].

Ciccarelli C, Pizzarelli F, Parlongo S, Maggiore Q.

Minerva Nefrol. 1979 Jul-Sep;26(3):321-3. Italian. No abstract available.

PMID:
262272
41.

[Vasoconstriction-volume bipolar analysis of arterial hypertension. Hemodynamic verification].

Zoccali C, Monzani G, Cerrai T, Maugeri C, Parlongo S, Maggiore Q.

Minerva Nefrol. 1979 Apr-Jun;26(2):221-4. Italian. No abstract available.

PMID:
471355
42.

[Oxalosis in the uremic phase].

Poggi A, Bonucci E, Brancaccio D, Sisca S, Scullica L, Romeo G, Ciccarelli C, Parlongo S, Maggiore Q.

Minerva Nefrol. 1979 Apr-Jun;26(2):125-9. Italian. No abstract available.

PMID:
471337
43.

Oxalate removal by dialysis and haemoperfusion.

Maggiore Q, Poggi A, Parlongo S, Cerrai T.

Proc Eur Dial Transplant Assoc. 1979;16:717-8. No abstract available.

PMID:
549019

Supplemental Content

Loading ...
Support Center